Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer
1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months ...
Tag: triple negative breast cancer
#VisualAbstract: Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a non-anthracycline regimen was 58% 2. The estimated ...
Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair ...
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
Click to read this study in Journal of Clinical Oncology.
#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes
1. Heterogeneity in histological profile linked to improved overall survival, chemotherapy response, and clinical course despite triple-negative receptor status in ...
#VisualAbstract: Chemotherapy in addition to local therapy may improve overall survival in patients aged 70 years or older with triple-negative breast cancer
Click to read the study in The Lancet Oncology
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
